135 related articles for article (PubMed ID: 21044639)
1. In-vivo histamine H3 receptor antagonism activates cellular signaling suggestive of symptomatic and disease modifying efficacy in Alzheimer's disease.
Bitner RS; Markosyan S; Nikkel AL; Brioni JD
Neuropharmacology; 2011; 60(2-3):460-6. PubMed ID: 21044639
[TBL] [Abstract][Full Text] [Related]
2. Selective alpha7 nicotinic acetylcholine receptor activation regulates glycogen synthase kinase3beta and decreases tau phosphorylation in vivo.
Bitner RS; Nikkel AL; Markosyan S; Otte S; Puttfarcken P; Gopalakrishnan M
Brain Res; 2009 Apr; 1265():65-74. PubMed ID: 19230830
[TBL] [Abstract][Full Text] [Related]
3. In vivo pharmacological characterization of a novel selective alpha7 neuronal nicotinic acetylcholine receptor agonist ABT-107: preclinical considerations in Alzheimer's disease.
Bitner RS; Bunnelle WH; Decker MW; Drescher KU; Kohlhaas KL; Markosyan S; Marsh KC; Nikkel AL; Browman K; Radek R; Anderson DJ; Buccafusco J; Gopalakrishnan M
J Pharmacol Exp Ther; 2010 Sep; 334(3):875-86. PubMed ID: 20504913
[TBL] [Abstract][Full Text] [Related]
4. Donepezil, an acetylcholine esterase inhibitor, and ABT-239, a histamine H3 receptor antagonist/inverse agonist, require the integrity of brain histamine system to exert biochemical and procognitive effects in the mouse.
Provensi G; Costa A; Passani MB; Blandina P
Neuropharmacology; 2016 Oct; 109():139-147. PubMed ID: 27291828
[TBL] [Abstract][Full Text] [Related]
5. Cyclic AMP response element-binding protein (CREB) phosphorylation: a mechanistic marker in the development of memory enhancing Alzheimer's disease therapeutics.
Scott Bitner R
Biochem Pharmacol; 2012 Mar; 83(6):705-14. PubMed ID: 22119240
[TBL] [Abstract][Full Text] [Related]
6. Histamine H3 receptor antagonism by ABT-239 attenuates kainic acid induced excitotoxicity in mice.
Bhowmik M; Saini N; Vohora D
Brain Res; 2014 Sep; 1581():129-40. PubMed ID: 24952295
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological properties of ABT-239 [4-(2-{2-[(2R)-2-Methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile]: II. Neurophysiological characterization and broad preclinical efficacy in cognition and schizophrenia of a potent and selective histamine H3 receptor antagonist.
Fox GB; Esbenshade TA; Pan JB; Radek RJ; Krueger KM; Yao BB; Browman KE; Buckley MJ; Ballard ME; Komater VA; Miner H; Zhang M; Faghih R; Rueter LE; Bitner RS; Drescher KU; Wetter J; Marsh K; Lemaire M; Porsolt RD; Bennani YL; Sullivan JP; Cowart MD; Decker MW; Hancock AA
J Pharmacol Exp Ther; 2005 Apr; 313(1):176-90. PubMed ID: 15608077
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological properties of ABT-239 [4-(2-{2-[(2R)-2-Methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile]: I. Potent and selective histamine H3 receptor antagonist with drug-like properties.
Esbenshade TA; Fox GB; Krueger KM; Miller TR; Kang CH; Denny LI; Witte DG; Yao BB; Pan L; Wetter J; Marsh K; Bennani YL; Cowart MD; Sullivan JP; Hancock AA
J Pharmacol Exp Ther; 2005 Apr; 313(1):165-75. PubMed ID: 15608078
[TBL] [Abstract][Full Text] [Related]
9. Discovery of histamine H3 antagonists for the treatment of cognitive disorders and Alzheimer's disease.
Brioni JD; Esbenshade TA; Garrison TR; Bitner SR; Cowart MD
J Pharmacol Exp Ther; 2011 Jan; 336(1):38-46. PubMed ID: 20864505
[TBL] [Abstract][Full Text] [Related]
10. Effects of the histamine H₃ receptor antagonist ABT-239 on cognition and nicotine-induced memory enhancement in mice.
Kruk M; Miszkiel J; McCreary AC; Przegaliński E; Filip M; Biała G
Pharmacol Rep; 2012; 64(6):1316-25. PubMed ID: 23406742
[TBL] [Abstract][Full Text] [Related]
11. GRK5 influences the phosphorylation of tau via GSK3β and contributes to Alzheimer's disease.
Zhao J; Li X; Chen X; Cai Y; Wang Y; Sun W; Mai H; Yang J; Fan W; Tang P; Ou M; Zhang Y; Huang X; Zhao B; Cui L
J Cell Physiol; 2019 Jul; 234(7):10411-10420. PubMed ID: 30511419
[TBL] [Abstract][Full Text] [Related]
12. Selective brain region activation by histamine H₃ receptor antagonist/inverse agonist ABT-239 enhances acetylcholine and histamine release and increases c-Fos expression.
Munari L; Provensi G; Passani MB; Blandina P
Neuropharmacology; 2013 Jul; 70():131-40. PubMed ID: 23380305
[TBL] [Abstract][Full Text] [Related]
13. Heteroreceptor Complexes Formed by Dopamine D
Rodríguez-Ruiz M; Moreno E; Moreno-Delgado D; Navarro G; Mallol J; Cortés A; Lluís C; Canela EI; Casadó V; McCormick PJ; Franco R
Mol Neurobiol; 2017 Aug; 54(6):4537-4550. PubMed ID: 27370794
[TBL] [Abstract][Full Text] [Related]
14. The Potent and Selective Histamine H3 Receptor Antagonist E169 Counteracts Cognitive Deficits and Mitigates Disturbances in the PI3K/AKT/GSK-3β Signaling Pathway in MK801-Induced Amnesia in Mice.
Abdalla S; Eissa N; Jayaprakash P; Beiram R; Kuder KJ; Łażewska D; Kieć-Kononowicz K; Sadek B
Int J Mol Sci; 2023 Aug; 24(16):. PubMed ID: 37628900
[TBL] [Abstract][Full Text] [Related]
15. GSK189254, a novel H3 receptor antagonist that binds to histamine H3 receptors in Alzheimer's disease brain and improves cognitive performance in preclinical models.
Medhurst AD; Atkins AR; Beresford IJ; Brackenborough K; Briggs MA; Calver AR; Cilia J; Cluderay JE; Crook B; Davis JB; Davis RK; Davis RP; Dawson LA; Foley AG; Gartlon J; Gonzalez MI; Heslop T; Hirst WD; Jennings C; Jones DN; Lacroix LP; Martyn A; Ociepka S; Ray A; Regan CM; Roberts JC; Schogger J; Southam E; Stean TO; Trail BK; Upton N; Wadsworth G; Wald JA; White T; Witherington J; Woolley ML; Worby A; Wilson DM
J Pharmacol Exp Ther; 2007 Jun; 321(3):1032-45. PubMed ID: 17327487
[TBL] [Abstract][Full Text] [Related]
16. Disease modifying effect of chronic oral treatment with a neurotrophic peptidergic compound in a triple transgenic mouse model of Alzheimer's disease.
Kazim SF; Blanchard J; Dai CL; Tung YC; LaFerla FM; Iqbal IG; Iqbal K
Neurobiol Dis; 2014 Nov; 71():110-30. PubMed ID: 25046994
[TBL] [Abstract][Full Text] [Related]
17. Broad-spectrum efficacy across cognitive domains by alpha7 nicotinic acetylcholine receptor agonism correlates with activation of ERK1/2 and CREB phosphorylation pathways.
Bitner RS; Bunnelle WH; Anderson DJ; Briggs CA; Buccafusco J; Curzon P; Decker MW; Frost JM; Gronlien JH; Gubbins E; Li J; Malysz J; Markosyan S; Marsh K; Meyer MD; Nikkel AL; Radek RJ; Robb HM; Timmermann D; Sullivan JP; Gopalakrishnan M
J Neurosci; 2007 Sep; 27(39):10578-87. PubMed ID: 17898229
[TBL] [Abstract][Full Text] [Related]
18. The Akt/GSK-3beta axis as a new signaling pathway of the histamine H(3) receptor.
Bongers G; Sallmen T; Passani MB; Mariottini C; Wendelin D; Lozada A; Marle Av; Navis M; Blandina P; Bakker RA; Panula P; Leurs R
J Neurochem; 2007 Oct; 103(1):248-58. PubMed ID: 17623045
[TBL] [Abstract][Full Text] [Related]
19. Role of GSK-3beta activation and alpha7 nAChRs in Abeta(1-42)-induced tau phosphorylation in PC12 cells.
Hu M; Waring JF; Gopalakrishnan M; Li J
J Neurochem; 2008 Aug; 106(3):1371-7. PubMed ID: 18485099
[TBL] [Abstract][Full Text] [Related]
20. Role of H3-receptor-mediated signaling in anxiety and cognition in wild-type and Apoe-/- mice.
Bongers G; Leurs R; Robertson J; Raber J
Neuropsychopharmacology; 2004 Mar; 29(3):441-9. PubMed ID: 14628000
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
